Half-Year 2022 Financial and Clinical Trials Update

zinpentraxin alfa (PRM-151, RG6354) Recombinant human innate immunity protein pentraxin-2 Indication Phase/study # of patients Phase II Idiopathic pulmonary fibrosis (IPF) Phase III STARSCAPE N=658 Myelofibrosis Phase II Design Primary endpoint ☐ N=117 Randomized, double-blind, placebo-controlled trial: 4-week screening period, 24-week randomized treatment period, 4-week follow-up visit (week 28) Zinpentraxin alfa at days 1, 3 and 5, then every 4 weeks vs placebo ▪ Least-squares mean change in FVC percentage of predicted value from baseline to week 28 • Study met primary endpoint • Data published in JAMA 2018;319(22):2299- Status CT Identifier 2307 and Lancet Respir Med 2019 Aug;7(8):657- 664 NCT02550873 " • N=125 Randomized, double-blind, placebo-controlled Multiple dose study of zinpentraxin alfa trial: 4-week screening period, 52-week randomized treatment period ■ Zinpentraxin alfa at days 1, 3 and 5, then every 4 weeks vs placebo •Absolute change from baseline to week 52 in FVC " FPI Q1 2021 NCT04552899 • Bone marrow response rate Study completed Q1 2021 NCT01981850 FVC-Forced vital capacity JAMA Journal of the American Medical Association 138 Roche Immunology

View entire presentation